You can buy or sell CytomX and other stocks, options, ETFs, and crypto commission-free!
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. Read More The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM) (NASDAQ: AXSM) Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) (NASDAQ: CPRX) CYCLERION THERA/SH (NASDAQ: CYCNV) (NASDAQ: CYCNV) Veracyte Inc (NASDAQ: VCYT) Down In The Dumps (Biotech stocks hitting 52-week lows on March 25) Adamas Pharmaceuticals Inc (NASDAQ: ADMS) (NASDAQ: ADMS) Assembly Biosciences Inc (NASDAQ: ...
Seeking AlphaMar 25
CytomX finance chief bids adieu
CytomX Therapeutics (NASDAQ:CTMX) announces that CFO Debanjan Ray will resign on May 15 to accept the CEO job at an unnamed biotech startup.
Seeking AlphaFeb 27
CytomX Therapeutics' (CTMX) CEO Sean McCarthy on Q4 2018 Results - Earnings Call Transcript
CytomX Therapeutics (NASDAQ:CTMX) Q4 2018 Earnings Conference Call February 27, 2019 5:00 PM ET Company Participants Chris Keenan - VP, IR Sean McCarthy - President, CEO & Chairman Debanjan Ray - CFO Conference Call Participants Alec Stranahan - Bank of America Merrill Lynch Boris Peaker - Cowen Robert Burns - H.C. Wainwright Mohit Bansal - Citi Jackson Harvey - Nomura Joe Catanzaro - Piper Jaffray Peter Lawson - SunTrust Robinson Operator Good afternoon, and welcome to the CytomX 2018 Full-Ye...
Expected May 9, After Hours